In 2015, the FDA approved talimogene laherparepvec (T-VEC or Imlygic), a second-generation oncolytic herpes simplex virus type 1 (HSV-1) armed with Granulocyte Macrophage colony-stimulating factor (GM-CSF) [34], for the treatment of metastatic melanoma, which was the first approved oncolytic viral immunotherapy, although there are several clinical trials of oncolytic viruses that cover almost all solid tumors, including lung cancer. The gene discussed is CSF2; the disease is lung carcinoma.